202108 Jan
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
Funding Rounds
202108 Jan
$150MSeries B

SHANGHAI, Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced today the closing of a $150 million Series B financing. Endocrinology is a large therapeutic area with significant unaddressed medical needs in Greater China, and there is a gap of treatment standard in comparison with US and EU," said Pony Lu, CEO and board member of VISEN Pharmaceuticals. "Our relationship with VISEN is a key element of our Vision 3x3 strategy to extend the global reach of our TransCon endocrinology rare disease product candidates and improve patients lives around the world." Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients lives. CDG Capital is the sole advisor of China Reform Conson Soochow Overseas Fund I L.P.. Its portfolio companies in healthcare sector include Innovent, Akeso, Tigermed, RemeGen, MicroPort CardioFlow, Antengene, Grail, etc.

  • HealthTech
  • Medical Equipment Software